Compare Ginkgo Bioworks Holdings Inc (DNA) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Texas Instruments Incorporated — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.51 (market cap $515.15M), while Texas Instruments Incorporated trades at $284.46 (market cap $256.11B). The key difference: Texas Instruments Incorporated is far larger — about 497.2× Ginkgo Bioworks Holdings Inc's market cap, and Texas Instruments Incorporated pays a 2.03% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | TXN | |
|---|---|---|
Market Cap | $515.15M | $256.11B |
Sector | Health | Technology |
52-Week High | $16.14 | $332.35 |
52-Week Low | $5.48 | $153.33 |
Enterprise Value | $617.10M | $263.16B |
Dividend Yield | — | 2.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.
DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.
Texas Instruments (TXN) trades at $281.24, down 1.69% over 24 hours, with a bullish technical signal from moving averages and recent price action above the 20-day average. Revenue grew to $17.68 billion in 2025, with net income of $5.00 billion and strong profitability margins. Recent news highlights CFO transition and AI-driven demand boosting data center revenue.
Outlook remains positive with analyst consensus price target of $333.10, implying 18% upside. Risks include high valuation multiples and increasing debt-to-asset ratio. The stock presents opportunity from AI infrastructure growth but faces margin pressure and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
